We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL.
- Authors
Westin, J.; Strati, P.; Chihara, D.; Pulsifer, B.; Tom, J.; Davis, R. E.; Lee, H. J.; Nair, R.; Rodriguez, A.; Hagemeister, F.; Flowers, C.; Nastoupil, L.; Feng, L.; Green, M.; Fayad, L.; Iyer, S.; Ahmed, S.; Steiner, R.
- Abstract
Patients who achieve less than a CR (Group B or D) will receive LTRA-CHOP for 6 cycles, for a planned 10 cycles of therapy for all patients. B Background: b Diffuse Large B-cell Lymphoma (DLBCL) is cured in ~60% of patients by a chemotherapy-based approach which is largely unchanged for decades.
- Subjects
DIFFUSE large B-cell lymphomas; RITUXIMAB; LENALIDOMIDE; CLINICAL trials
- Publication
Hematological Oncology, 2023, Vol 41, p837
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3166_OT17